Efficacy of second generation direct-acting antiviral agents for treatment naïve hepatitis C genotype 1: A systematic review and network meta-analysis

PLoS ONE

Volumn 10, Issue 12, 2015, Pages

  Suwanthawornkul, Thanthima ^a   Anothaisintawee, Thunyarat ^b   Sobhonslidsuk, Abhasnee ^b   Thakkinstian, Ammarin ^b   Teerawattananon, Yot ^a  

^a MINISTRY OF PUBLIC HEALTH   (Thailand)

^b MAHIDOL UNIVERSITY   (Thailand)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; DACLATASVIR; DASABUVIR PLUS OMBITASVIR PLUS PARITAPREVIR PLUS RITONAVIR; DIRECT ACTING ANTIVIRAL AGENT; LEDIPASVIR; PEGINTERFERON ALPHA2B PLUS RIBAVIRIN; RIBAVIRIN; SIMEPREVIR; SOFOSBUVIR; UNCLASSIFIED DRUG;

ANEMIA; ARTICLE; DRUG EFFICACY; DRUG SAFETY; FATIGUE; FOOD AND DRUG ADMINISTRATION; HEPATITIS C; HEPATITIS C VIRUS GENOTYPE 1; HUMAN; META ANALYSIS; RISK ASSESSMENT; SYSTEMATIC REVIEW; TREATMENT DURATION; TREATMENT INDICATION; TREATMENT OUTCOME; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; COMBINATION DRUG THERAPY; GENETICS; GENOTYPE; HEPACIVIRUS; ODDS RATIO; PUBLISHING; TIME FACTOR; VIROLOGY; VIRUS LOAD;

ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; FATIGUE; GENOTYPE; HEPACIVIRUS; HEPATITIS C; HUMANS; ODDS RATIO; PUBLICATION BIAS; TIME FACTORS; TREATMENT OUTCOME; VIRAL LOAD;

EID: 84956923297     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0145953     Document Type: Article

References (32)

1. World Health Organization. Call To Action To Scale Up Global Hepatitis Response Geneva, Switzerland2014 [cited 2015 29th March]. Available from: http://www.who.int/hiv/mediacentre/news/hep-calltoaction-new.pdf.
2. World Health Organization. Recommendations from existing WHO guidance: Prevention Guidelines for the prevention, care and treatment of persons with chronic hepatitis B infection. France: World Health Organization; 2015. p. 87.
3. World Health Organization. Sixty-seventh World Health Assembly 2014 [cited 2015 29th March]. Available from: http://www.who.int/mediacentre/factsheets/fs164/en/.
4. Lawitz E, Lalezari JP, Hassanein T, Kowdley KV, Poordad FF, Sheikh AM, et al. Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: A randomised, double-blind, phase 2 trial. The Lancet Infectious Diseases. 2013;13(5):401-8. doi: 10.1016/S1473-3099 (13) 70033-1 PMID: 23499158
5. Kowdley KV, Lawitz E, Crespo I, Hassanein T, Davis MN, DeMicco M, et al. Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naive patients with hepatitis C genotype-1 infection (ATOMIC): an open-label, randomised, multicentre phase 2 trial. Lancet. 2013;381(9883):2100-7. Epub 2013/03/19. doi: 10.1016/s0140-6736 (13) 60247-0 PMID: 23499440.
6. Lawitz E, Gane EJ. Sofosbuvir for previously untreated chronic hepatitis C infection. The New England journal of medicine. 2013;369(7):678-9. Epub 2013/08/16. doi: 10.1056/NEJMc1307641 PMID: 23944316.
7. Pol S, Ghalib RH, Rustgi VK, Martorell C, Everson GT, Tatum HA, et al. Daclatasvir for previously untreated chronic hepatitis C genotype-1 infection: a randomised, parallel-group, double-blind, placebocontrolled, dose-finding, phase 2a trial. The Lancet Infectious diseases. 2012;12(9):671-7. Epub 2012/06/21. doi: 10.1016/s1473-3099 (12) 70138-x PMID: 22714001.
8. Ghany MG, Strader DB, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology. 2009;49(4):1335-74. Epub 2009/03/31. doi: 10.1002/hep. 22759 PMID: 19330875.
9. Higgins JPT, Altman DG, Gøtzsche PC, Jüni P, Moher D, Oxman AD, et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials2011 2011-10-18 10:55:48.
10. Hayashi N, Seto C, Kato M, Komada Y, Goto S. Once-daily simeprevir (TMC435) with peginterferon/ribavirin for treatment-naïve hepatitis C genotype 1-infected patients in Japan: The DRAGON study. Journal of Gastroenterology. 2014;49(1):138-47. doi: 10.1007/s00535-013-0875-1 PMID: 24005956
11. Fried MW, Buti M, Dore GJ, Flisiak R, Ferenci P, Jacobson I, et al. Once-daily simeprevir (TMC435) with pegylated interferon and ribavirin in treatment-naïve genotype 1 hepatitis C: The randomized PILLAR study. Hepatology. 2013;58(6):1918-29. doi: 10.1002/hep. 26641 PMID: 23907700
12. Hayashi N, Izumi N, Kumada H, Okanoue T, Tsubouchi H, Yatsuhashi H, et al. Simeprevir with peginterferon/ribavirin for treatment-naïve hepatitis C genotype 1 patients in Japan: CONCERTO-1, a phase III trial. Journal of Hepatology. 2014;61(2):219-27. doi: 10.1016/j.jhep. 2014.04.004 PMID: 24727123
13. Jacobson IM, Dore GJ, Foster GR, Fried MW, Radu M, Rafalsky VV, et al. Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): A phase 3, randomised, double-blind, placebo-controlled trial. The Lancet. 2014;384(9941):403-13.
14. Manns M, Marcellin P, Poordad F, De Araujo ESA, Buti M, Horsmans Y, et al. Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): A randomised, double-blind, placebo-controlled phase 3 trial. The Lancet. 2014;384(9941):414-26.
15. Pol S, Ghalib RH, Rustgi VK, Martorell C, Everson GT, Tatum HA, et al. Daclatasvir for previously untreated chronic hepatitis C genotype-1 infection: A randomised, parallel-group, double-blind, placebocontrolled, dose-finding, phase 2a trial. The Lancet Infectious Diseases. 2012;12(9):671-7. doi: 10.1016/S1473-3099 (12) 70138-X PMID: 22714001
16. Hézode C, Hirschfield GM, Ghesquiere W, Sievert W, Rodriguez-Torres M, Shafran SD, et al. Daclatasvir plus peginterferon alfa and ribavirin for treatment-naive chronic hepatitis C genotype 1 or 4 infection: A randomised study. Gut. 2014.
17. Kowdley KV, Gordon SC, Reddy KR, Rossaro L, Bernstein DE, Lawitz E, et al. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. New England Journal of Medicine. 2014;370(20):1879-88. doi: 10.1056/NEJMoa1402355 PMID: 24720702
18. Afdhal N, Zeuzem S, Kwo P, Chojkier M, Gitlin N, Puoti M, et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. The New England journal of medicine. 2014;370(20):1889-98. Epub 2014/04/15. doi: 10.1056/NEJMoa1402454 PMID: 24725239.
19. Lawitz E, Poordad FF, Pang PS, Hyland RH, Ding X, Mo H, et al. Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): An open-label, randomised, phase 2 trial. The Lancet. 2014;383(9916):515-23.
20. Lawitz E, Sulkowski MS, Ghalib R, Rodriguez-Torres M, Younossi ZM, Corregidor A, et al. Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study. The Lancet. 2014.
21. Sulkowski MS, Gardiner DF, Rodriguez-Torres M, Reddy KR, Hassanein T, Jacobson I, et al. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. New England Journal of Medicine. 2014;370(3):211-21. doi: 10.1056/NEJMoa1306218 PMID: 24428467
22. Rodriguez-Torres M, Lawitz E, Kowdley KV, Nelson DR, Dejesus E, McHutchison JG, et al. Sofosbuvir (GS-7977) plus peginterferon/ribavirin in treatment-naive patients with HCV genotype 1: a randomized, 28-day, dose-ranging trial. J Hepatol. 2013;58(4):663-8. Epub 2012/11/28. doi: 10.1016/j.jhep. 2012. 11.018 PMID: 23183528.
23. Mizokami M, Yokosuka O, Takehara T, Sakamoto N, Korenaga M, Mochizuki H, et al. Ledipasvir and sofosbuvir fixed-dose combination with and without ribavirin for 12 weeks in treatment-naive and previously treated Japanese patients with genotype 1 hepatitis C: an open-label, randomised, phase 3 trial. The Lancet Infectious Diseases. 2015;15(6):645-53. doi: 10.1016/S1473-3099 (15) 70099-X PMID: 25863559
24. Kowdley KV, Lawitz E, Poordad F, Cohen DE, Nelson DR, Zeuzem S, et al. Phase 2b Trial of Interferonfree Therapy for Hepatitis C Virus Genotype 1. New England Journal of Medicine. 2014;370(3):222-32. doi: 10.1056/NEJMoa1306227 PMID: 24428468.
25. Kohli A, Shaffer A, Sherman A, Kottilil S. Treatment of hepatitis C: a systematic review. Jama. 2014;312(6):631-40. Epub 2014/08/15. doi: 10.1001/jama.2014.7085 PMID: 25117132.
26. Feeney ER, Chung RT. Antiviral treatment of hepatitis C. BMJ (Clinical research ed). 2014;348:g3308. Epub 2014/07/09. doi: 10.1136/bmj.g3308 PMID: 25002352.
27. Bansal S, Singal AK, McGuire BM, Anand BS. Impact of all oral anti-hepatitis C virus therapy: A metaanalysis. World J Hepatol. 2015;7(5):806-13. Epub 2015/04/29. doi: 10.4254/wjh.v7.i5.806 PMID: 25914781; PubMed Central PMCID: PMCPmc4404386.
28. Cooper C, Lester R, Thorlund K, Druyts E, El Khoury AC, Yaya S, et al. Direct-acting antiviral therapies for hepatitis C genotype 1 infection: a multiple treatment comparison meta-analysis. QJM: monthly journal of the Association of Physicians. 2013;106(2):153-63. Epub 2012/11/20. doi: 10.1093/qjmed/hcs214 PMID: 23159839; PubMed Central PMCID: PMCPmc3550598.
29. Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature. 2009;461(7262):399-401. Epub 2009/08/18. doi: 10.1038/nature08309 PMID: 19684573.
30. Thomas DL, Thio CL, Martin MP, Qi Y, Ge D, O'Huigin C, et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature. 2009;461(7265):798-801. Epub 2009/09/18. doi: 10. 1038/nature08463 PMID: 19759533; PubMed Central PMCID: PMCPmc3172006.
31. Pollack A. FDA approves pill to treat hepatitis C: New York Times; 2013 [cited 2015 3rd March]. Available from: www.nytimes.com/2013/12/07/business/fda-approves-pill-to-treat-heaptitis-c.html.
32. Malone DC, Tran TT, Poordad FF. Cost-efficacy analysis of peginterferon alfa-2b plus ribavirin compared with peginterferon alfa-2a plus ribavirin for the treatment of chronic hepatitis C. Journal of managed care pharmacy: JMCP. 2005;11(8):687-94. Epub 2005/10/01. PMID: 16194133.